Stock Splits
By The Online Investor Staff, updated Fri., Jan. 24, 7:19 AM
| This Slide: #8 of 25 |
Slide #8. Protalix BioTherapeutics, Inc. (AMEX:PLX) — 1 for 10 Reverse Split
Announced:
12/9/2019
Stock Split:
1 for 10
Record Date:
12/18/2019
Pay Date:
12/19/2019
PLX Optionable?:
Yes
Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx® protein expression system. Co. has developed taliglucerase alfa for the treatment of Gaucher disease. Co.'s product pipeline includes, among other candidates, pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and OPRX-106, Co.'s oral anti Tumor, Necrosis Factor product candidate. 
PLX Detailed Information Page & Split History »
|
|||||||||
Open the PLX Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 84th percentile
(ranked higher than approx. 84% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
